Breaks Categories: News

ThursdayJan 21, 2021 3:34 pm

PsychedelicNewsBreaks – Following a Year of Success, Psychedelics Could Emerge Large in 2021

The year 2020 was a great year for psychedelics; more than two dozen companies focusing on psychedelics in some manner became publicly listed. That success certainly seems to have sparked interest in what the sector will see in 2021. A recent Benzinga article, titled “What Will the Psychedelics Space Look Like in 2021? Experts Weigh In” noted that as psychedelics grow closer to receiving federal legalization, scientific, regulatory and corporate developments are almost daily news. Experts in the field are looking for new clinical and R&D initiatives to emerge, investment opportunities to increase, and public acceptance to expand. In addition,…

Continue Reading

ThursdayJan 14, 2021 9:25 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Upcoming Study on Psilocybin-Based Nasal Gel, Oral Tablets and Capsules

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released the timetable and milestones for a proprietary study. The study is designed to evaluate the formulation, manufacturing and clinical bioavailability of psilocybin-based, rapid-onset active treatments for a nasal gel as well as oral tablets and capsules that will be used as an investigational product. PULL anticipates that the study will be conducted by Dr. Alexander MacGregor at the Toronto Institute of Pharmaceutical Technology (“TIPT”); MacGregor is a scientific advisor for Pure Extracts. During the study, the company will be evaluating several…

Continue Reading

MondayJan 11, 2021 11:47 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces New CFO, General Counsel

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) chairman and CEO Roger McIntyre today announced the company's appointment of Stephen R. Brooks as its new chief financial officer and Peter Rizakos as the firm's new general counsel. According to the update, these appointments complete the company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.  "These new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response…

Continue Reading

MondayJan 11, 2021 11:19 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for its upcoming sponsored clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction. Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug development programs is potentially…

Continue Reading

FridayJan 08, 2021 11:31 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Article Outlining Future Potential in Novel Agents for Bipolar Disorders

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article, “Bipolar Disorders” is published in The Lancet – one of the world's best-known and most reputable scientific journals in medicine. According to the update, the article contributes to The Lancet 's collection of peer-reviewed seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies." "The availability of so-called rapid-onset treatments (e.g., ketamine) and treatments that could mitigate suicidality is crucial to clinical settings,"…

Continue Reading

ThursdayJan 07, 2021 11:33 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Listing on OTC Markets, Now Trading Under PRXTF Symbol

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, recently received approval from OTC Markets and is  now trading under the ticker symbol PRXTF (“PRXTF”). OTC Markets is recognized for offering Canadian companies the benefits of being publicly traded in the United States but with lower cost and complexity than a U.S. exchange listing. To be eligible to list on the OTC Exchange, Canadian companies must undergo an annual verification and management certification process and be up-to-date with their SEDAR reporting. Moving forward, Pure Extracts will continue to trade on…

Continue Reading

WednesdayJan 06, 2021 2:08 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral film delivery mechanism covering all psychedelic molecules delivered through oral films; a delivery technology covering various chemically synthesized psychedelic molecules; multiple patent applications for deuterated psychedelic molecules and analogues; and a patent application for platforms that create supportive treatment regimens. The company also announced that…

Continue Reading

WednesdayDec 30, 2020 10:33 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. According to the update, the study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to Pure Extracts. The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms…

Continue Reading

WednesdayDec 30, 2020 10:25 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020. According to the update, a copy of the consolidated financial statements prepared in accordance with International Financial Reporting Standards, as well as the corresponding management’s discussion and analysis for the three months ended Oct. 31, 2020, can be found under Cybin’s profile at www.SEDAR.com. To view the full press release, visit https://ibn.fm/br5Uw About Cybin Inc. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments…

Continue Reading

WednesdayDec 16, 2020 11:04 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Begins Facility Build-Out, Prepares to Apply for Dealer’s Licence

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company, has begun build-out work on the fourth unit in is extraction facility; in addition, the company is preparing to submit application to Health Canada requesting a dealer's licence under the Controlled Drugs and Substances Act (“CDSA”), the government entity that provides the framework for legal access to controlled substances, including the control and regulation of production, distribution and sale of psilocybin. Based on guidelines, a company must have a Health Canada-issued licence in order to conduct business with controlled substances. A license could allow Pure Extracts to procure controlled substances; research…

Continue Reading